The clinical research firm raised its full-year guidance after reporting record net bookings and lower cancellations in Q2 2026.
Medpace increased its 2026 revenue forecast to a range of $2.805 billion to $2.885 billion, citing a constructive business environment and reduced cancellations. The update follows a record quarter for net bookings in Q2 2026.
Management attributed the strength to well-behaved cancellations and robust demand for clinical research services. The prior outlook was not disclosed, but the company highlighted consistent growth trends in recent periods.
Shares showed limited immediate reaction following the announcement during the earnings call.